• Tue news: Regeneron fails to block Eylea biosimilar. Inside the GLP-1 price war. Novartis inks $1B biobucks deal. UCB/Biogen lupus drug. Lilly Alzheimer’s drug approved in Japan. See more on our front page

Selling off pipeline candidates? seriously....


<







The company also sell some drug candidates to competitors.

And the hits keep coming

http://asia.nikkei.com/Markets/Tokyo-Market/Eisai-boosting-cash-holdings-to-maintain-dividends

So for all of you who have not been at the table for Business Development deals.
This is how it goes, specifically for Eisai, there is no tomorrow.
You mortgage the short term so you can live sometime down the road.

The problem for all you idiots at US Eisai; you are not part of the plan.
If you stay, you will get a pink slip and the useless idiots in HR will turn
the lights out on their way out- when there is no left.

Enjoy
 








So for all of you who have not been at the table for Business Development deals.
This is how it goes, specifically for Eisai, there is no tomorrow.
You mortgage the short term so you can live sometime down the road.

The problem for all you idiots at US Eisai; you are not part of the plan.
If you stay, you will get a pink slip and the useless idiots in HR will turn
the lights out on their way out- when there is no left.

Enjoy

The pathetic thing is that Scott and Ciriello actually are stupid enough to think that the Japanese are loyal to them. Coats thought so too.